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Gypenosides extracted from Gynostemma pentaphyllum (Thunb.) Makino have significant role in reducing serum lipid level and
treating fatty liver diseases, however, without clear mechanism. As gypenosides share the similar core structures with bile acids
(the endogenous ligands of nuclear receptor FXR), we hypothesize that gypenosides may improve hypercholesterolemia via FXRmediated bile acids signaling. The present study was designed to validate the role of gypenosides in reducing levels of serum total
cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), as well as in regulating bile acids homeostasis and related gene
expression levels. The C57BL/6 male mice were divided into four groups. Mice in groups ND and HFD were fed with normal diet
and high fat diet for 38 weeks, respectively. In groups HFD+GP and HFD+ST, mice were fed with high fat diet for 38 weeks and
treated with gypenosides and simvastatin (positive control) from weeks 16 to 38, respectively. Serum TC and LDL-C levels were
assayed by commercially available kits. Expression levels of genes were tested by the quantitative real-time PCR. The LC-MS/MS was
applied to quantify major bile acids in mice livers. Our results showed that gypenosides significantly decreased serum TC and LDLC levels. The gene expression level of Shp was downregulated while the levels of Cyp7a1, Cyp8b1, Fxr, Lrh1, Jnk1/2, and Erk1/2 were
upregulated by gypenosides. Indicated by LC-MS/MS technology, gypenosides increased the hepatic levels of several free bile acids
and most taurine-conjugated bile acids while decreasing glycine-conjugated bile acids levels. In addition, gypenosides decreased
the CA/CDCA ratio. Gypenosides may improve the abnormal lipid profile of HFD-fed mice via two pathways: (1) enhancing the
bile acids biosynthesis from cholesterol; (2) decreasing the CA/CDCA ratio which is positively related to cholesterol absorption.

1. Introduction
Hypercholesterolemia is associated with various diseases in
hepatic, enteric, and cardiovascular systems [1]. Medicines
such as statins, bile acid sequestrates, and PSCK9 inhibitors
have been used to treat hypercholesterolemia for years,
however, accompanied by various adverse drug events [2].
Gypenosides are extracted from the plant Gynostemma
(G.) pentaphyllum (Thunb.) Makino that is distributed in

China, Korea, Japan, and other Southeast Asian countries
[3, 4]. To data, gypenosides reduce serum cholesterol, triglycerides, and blood glucose levels without significant adverse
drug effect [5–11]. At the time of writing, around 100 gypenosides have been identified from this plant, constructing a
potential drug candidate’s pool for drug discovery and development. However, as the mechanism of gypenosides action in
treating these diseases is still unclear, there is little progress on
drug screening and development from gypenosides so far.

2
Gypenosides share the core structure of dammaranetype triterpene which is similar to the core structures of
endogenous bile acids. Bile acids mediate the absorption of
fat and cholesterol and regulate the lipid and carbohydrate
metabolisms [12, 13]. In the livers, cholesterol is biotransformed to various bile acids by a serials enzymes involving
CYP7A1, CTP8B1, and CYP27A1 [14, 15]. This process is
sensitively regulated by farnesoid X receptor (FXR), a nuclear
receptor regulating lipid and carbohydrate homeostasis [16–
18]. Thus, regulation of FXR-mediated bile acids homeostasis
could be a potential mechanism explaining the effect of
gypenosides on improving lipid and carbohydrate profiles.
Gypenosides are recognized as the relatives of ginsenosides
with similar core structures. A couple ginsenosides showed
significant role in regulation of CYP7A1, a rate-limit enzyme
of bile acids biosynthesis [19]. Guggulsterone, a compound
isolated from an Indian plant and also with the similar
structure of gypenosides core, was reported to be the ligand
of FXR [20].
In the present study, we aimed to validate the role
of gypenosides on cholesterol regulation and investigate
their effect on hepatic bile acids homeostasis at both gene
expression and bile acids quantification level. Once a new
mechanism of action and enzyme target is identified in our
study, screening of FXR ligands may become an effective
way to develop new drugs from gypenosides. Since classic
enterohepatic regulation of bile acids exists, some enteric
genes regulating bile acids pool profile were also checked.
An ultraperformance liquid chromatography coupled with
a triple quadruple tandem mass spectrometry was used to
quantify 14 major bile acids molecules.

2. Materials And Methods
2.1. Materials. Gypenosides (purity > 98% assayed by UV)
were purchased from Zhongxin Biotechnology Ltd. (Xian,
Shanxi Province, China). Simvastatin tablets (20 mg/Tablet)
were purchased from Xinqi Pharmaceutical Ltd. (Caoxian,
Shandong Province, China). Normal diet (23.2% of calories
from protein, 12.1% from fat, and 64.7% from carbohydrate)
and high fat diet (20.0% of calories from protein, 60.0%
from fat, and 20.0% from carbohydrate) were purchased from
Research Diets Inc. (New Brunswick, NJ). DEPC water was
purchased from Zoman Biotechnology Co., Ltd. (Beijing,
China).
2.2. Quality Check of Gypenosides. An HPLC-PDA system
was used to check the quality of gypenosides fed to mice in
the present study. Gypenosides (250 mg) were dissolved in
methanol (10 mL) to prepare the sample solution. An aliquot
of 10 𝜇L of the sample solution was injected into a Synergi 4
𝜇 MAX-RP 80R column (250 × 4.6 mm, 4 𝜇m) equipped in
HPLC system (Agilent 1260, Santa Clara, CA) for separation.
The column temperature and the flow rate were set at 30∘ C
and 0.6 mL/min, respectively. Water (A) and acetonitrile (B)
were used for elution with the following gradient: 0-1 min,
A:B = 70:30; 1-2 min, A:B = 65:35; 2-22 min, A:B = 50:50; 2238 min, A:B = 20:80; 38-45 min, A:B = 10:90; 45-46 min, A:B
= 5:95. A PDA detector was used with wavelength ranging
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from 190 nm to 400 nm. Both the chromatograms and the
UV spectrums were recorded.
2.3. Animal Experiments. Male C57BL/6 mice (23-25 g) were
purchased from Huafu Kang Biological Technology Ltd.
(Beijing, China; approval number: SCXK 2014-0004). All
the animals were kept in the well-controlled animal room
on the SPF level. Room temperature was set to 21 - 23∘ C,
while the humidity was set to 50%-60%. A 12-hour light/dark
cycle was used and animals were free to access food and
water. Mice were divided into 4 groups (𝑛 = 5-10 per
group). Two of these groups were treated with normal diet
(ND) and high fat diet (HFD) for 38 weeks, respectively.
The other two groups were treated with HFD for 38 weeks
while orally being treated with GPs (HFD+GP, 250 mg/Kg)
and simvastatin (HFD+ST, 20 mg/Kg) from weeks 16 to 38,
respectively. The group treated with simvastatin was used as
the positive control for lipid regulation. In our previous pilot
study, the hypercholesterolemia and hyperglycemia model
could be established at week 16 of HFD treatment. To confirm
this time point, we used additional two groups of mice. These
two additional groups of mice were treated with normal diet
and high fat diet for 16 weeks, respectively. Mice in HFD+GP
and HFD+ST groups were given gypenosides and simvastatin
daily, respectively, while mice in ND and HFD groups were
given 0.1% of CMC-Na solution (medium used to suspend
gypenosides and simvastatin in water) with the equivalent
volume. At the end point of the experiment, mice were
anesthetized by 7% chloral hydrate (0.05 mL/10g). Whole
blood, livers, and small intestines were collected or harvested.
Blood was centrifuged at 3,500 rpm for 10 min after an
incubation at room temperature for 1 hour to isolate serum.
Once harvested, livers were cut to small pieces. One piece of
liver was fixed in 10% formalin for pathological examination.
All of the other samples were transferred to liquid nitrogen
immediately for a quick frozen and transferred to -80∘ C
freezer for long term storage. All procedures involving the
use of laboratory animals were in accordance with the
requirements of Animal Experiment Ethics Committee of
Zunyi Medical University.
2.4. Histopathology Examination of Liver Tissues. After 24
hours, the fixed liver tissues were embedded in the wax (Leica
EG1150, Wetzlar, Germany) and then cut into slices of 6–8 𝜇m
by a Leica RM2245 Biosystems (Wetzlar, Germany). Tissue
slices were washed, dehydrated, and stained by hematoxylin
and eosin (HE) for microscopic examination (Olympus
BX43, Tokyo, Japan, × 40).
2.5. Evaluation of Lipid Profiles in Serum. Serum total
cholesterol (TC) and low density lipoprotein cholesterol
(LDL-C) were determined by using kits purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu
Province, China).
2.6. Expression Levels of Genes Involved in Bile Acids Regulation. Total RNA from mouse liver tissues and duodenum
were extracted following our previously used procedures.
Liver tissues of around 20 mg were thawed in 1mL of
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Table 1: Primers for real-time PCR assays.
Gene
Cyp7a1
Cyp8b1
Nr1h4
Nr0b2
Nr5a2
Hnf4𝛼
Mapk8
Mapk9
Mapk1
Mapk3
Fgfr4
Gapdh

Forward Primers
GAGCCCTGAAGCAATGAAAG
GGACAGCCTATCCTTGGTGA
TTCCTCAAGTTCAGCCACAG
GGAGTCTTTCTGGAGCCTTG
TCAGTTCGATCAGCGGGAGTTTGT
GTGCTTCCGGGCTGGCATGAA
CGTGGACTTATGGTCTGTGG
TGCGATTGAAGAGTGGAAAG
TCAGTCCTTTTGAGCACCAG
TCCATCGACATCTGGTCTGT
GTCTCCGAGATGGAGGTGAT
TGTGTCCGTCGTGGATCTGA

Reverse primers
GCTGTCCGGATATTCAAGGA
GACGGAACTTCCTGAACAGC
TCGCCTGAGTTCATAGATGC
ATCTGGGTTGAAGAGGATCG
TGCAGGTTCTCCAGGTTCTTCACA
AGGTGATCTGCTGGGACAGAACC
AGAGGATTTTGTGGCAAACC
TGAAGGCTGGTCTTTTACCC
TCATTTGCTCAATGGTTGG
AGCTGGTCCAGGTAGTGCTT
CCAGCAGGTTGATGATGTTC
CCTGCTTCACCACCTTCTTGA

Trizol reagent. After homogenizing on ice, the homogenates
were centrifuged and the upper layer was washed by 200
𝜇L of chloroform. Then 500 mL of isopropanol was used
to precipitate RNA. Precipitates were washed with 75% of
alcohol and then dissolved with 30 𝜇L of DEPC water after
evaporating all alcohol. A Nanodrop spectrophotometer was
used to quantify RNA samples. For each sample, 1 𝜇g of RNA
was used to make cDNA following the procedure indicated by
PrimeScript RT reagent kit (Company, City, TaKaRa, Japan)
on a Mastercycler Gradient PCR Thermal cycler (Eppendorf
Scientific, Inc., Germany). The temperature program for
reverse transcription was set as follows: 25∘ C for 10 min, 37∘ C
for 2 hours, and 85∘ C for 5 min.
The real-time polymerase chain reaction (RT-PCR) was
performed by using 2∗ SYBR Green Supermix (Bio-Rad, Germany) on a CFX96 RT-PCR System (C1000 Touch, BioRad,
Germany). The RT-PCR parameters were as follows: 3 min,
95∘ C, and 1 cycle; 10 s at 95∘ C plus 45 s at 60∘ C, 39 cycles.
The melting curve analysis consisted of 5 s at 55∘ C followed
by heating up to 95∘ C with a ramp rate of 0.5∘ C / 5 s. Names
and corresponding primer sequences of genes checked in the
present study were shown in Table 1. Expression levels of
GAPDH in each sample were used as internal reference.

of B from 14 to 14.5 min; 25% of B from 14.5 to 17.5 min; 2550% of B from 17.5 to 18 min; 50% of B from 18 to 22 min;
50-80% of B from 22 to 22.5 min; 80% of B from 22.5 to 24.5
min; 80-100% of B from 24.5 to 25 min; 100% of B from 25 to
27 min; 100-5% of B from 27 to 28 min; and 5% of B from 28 to
33 min. The injection volume was 10 𝜇L, and the flow rate was
set at 0.3 mL/min. Parameters of the ESI ion source were as
follows: negative mode; gas temp: 326∘ C, gas flow: 12 L/min,
nebulizer pressure: 55 psi, and capillary voltage: 3500 V. The
mass analyzer was set as the SIM mode to capture the [M-H]ions of expected BAs. Peak areas of each observed BAs were
used for comparison and statistical analysis among groups.

2.7. Quantification of Hepatic Bile Acids. Approximately 100
mg of liver tissues was homogenized in 300 𝜇L of acetonitrile
on ice. The homogenates were centrifuged at 14,300 rpm and
4∘ C for 10 min. An aliquot of 250 𝜇L of supernatants was
evaporated by nitrogen gas blow and dissolved in 50% of
methanol (100 𝜇L). After centrifugation at 14,300 rpm and
4∘ C for 10 min, the supernatants were used for quantification.
Quantifications of BAs were performed on a Triple Quad
UPLC-MS/MS system (Agilent 6420, Santa Clara, CA). A
CQUITY UPLC BEH C18 (1.7 𝜇m, 100 × 2.1 mm) column was
used for BAs separation. The chromatographic parameters
were modified from the published method [15]. The column
compartment was maintained at 45∘ C. The mobile phases
consisted of solvents A (10 mM of ammonium acetate in 20%
acetonitrile) and B (10 mM of ammonium acetate in 80%
acetonitrile). The elution gradient program was set as follows:
5% of B from 0 to 5 min; 5-14% of B from 5 to 14 min; 14–25%

3.1. Quality Analysis of The Gypenosides Used in the Present
Study. A fingerprint of gypenosides was obtained from a
HPLC-DAD system (Supplemental File 1). In total, 35 peaks
were observed with S/N ratio values more than 10. Most
peaks showed UV absorption patterns of end absorption,
which were consistent with the properties of gypenosides.
Represented UV spectrums of peak 7, peak 10, peak 20, peak
21, peak 24, peak 25, peak 26, and peak 30 were showed in part
B of Supplemental File 1. All of these peaks had the relatively
high amount in the gypenosides indicated by the peak area
values. The purity of the gypenosides was more than 98%
assayed by the ultraviolet spectrometry.

2.8. Statistical Analysis. All data were shown as mean ± SEM.
Statistical analyses between two groups were performed using
Student’s t-test while multiple comparisons were performed
using one-way ANOVA in the SPSS Statistics 18.0 (IBM,
Chicago, USA). A p value less than 0.05 was considered as
statistically significant. Principal component analysis (PCA)
was performed using the “pca” function in mixOmics package of the R program (i386, 3.3.3).

3. Results

3.2. Preparation of Hypercholesterolemia Model. The high fat
diet treatment significantly increased mouse body weight
levels after 16 weeks (Figure 1(a)). In addition, TC and LDLC levels were also increased by high fat diet (Figure 1(b)). In
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Figure 1: High fat diet induced hypercholesterolemia mouse models and fatty livers. (a) Mice body weight levels were increased significantly
by high fat diet at week 16. (b) Serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels were induced by high fat
diet at week 16. (c) HE staining of liver tissues showed an obvious lipid accumulation in hepatocytes of mice treated by high fat diet for 16
weeks. The images were shown as 40 times enlargement. W: week; ND: normal diet group; HFD: high fat diet group. Data were presented as
mean ± SEM. ∗ 𝑝 < 0.05.

mouse livers, fat accumulation was observed (Figure 1(c)) and
the portal area and central vein showed diffuse adipose hollow spaces (Figure 1(c)). Therefore, the hypercholesterolemia
model was confirmed for this study.
3.3. Effects of Gypenosides on Lipid Regulation. High fat
diet significantly increased the TC and LDL-C levels in
mouse serum (Figure 2(a)). After treatment, gypenosides and
simvastatin successfully decreased the abnormally elevated
TC and LDL-C levels. In addition, HE staining showed that
the lipid accumulation in mouse hepatocytes was observed
before treatment and then disappeared in mouse livers after
receiving gypenosides (Figure 2(b)). These findings suggested
that gypenosides may play a role in the lipid regulation, in
particular on cholesterol reducing.
3.4. Gypenosides Altered the Hepatic Gene Expression Levels pf
Cyp7a1 and Cyp8b1, Genes Encoding Enzymes Limiting Rate of
Bile Acids Biosynthesis. High fat diet reduced the hepatic gene
expression levels of Cyp7a1 and Cyp8b1 by times. The livers

of mouse treated with gypenosides showed a significantly
higher gene expression of Cyp7a1 compare to HFD group
and the ND group (Figure 3). Gypenosides also increased the
hepatic gene expression level of Cyp8b1 in mouse treated with
high fat diet; however, they did not recover it to the level of
ND group.
3.5. Gypenosides Altered the Hepatic Expression Levels of Genes
Involved in Hepatic Regulation Pathway of Bile Acids Homeostasis. Fxr, Shp, Lrh1, and Hnf4𝛼 encode four important
factors regulating bile acids homeostasis in mouse livers.
High fat diet treatment widely inhibited the expression levels
of these mouse hepatic genes. Gypenosides recovered the
gene expression levels of Fxr and Lrh1 to the levels of mice in
ND group (Figure 4). However, gypenosides failed to change
the gene expression levels of mouse hepatic Hnf4𝛼 in mice
treated with high fat diet. Notably, gypenosides repressed
the gene expression levels of Shp, an important participator
of bile acids biosynthesis regulation, compared to HFD
group.
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Figure 2: Gypenosides reversed the abnormal mouse serum and hepatic lipid homeostasis. (a) Both gypenosides and simvastatin reduced
the serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels in serum of mice treated with high fat diet. (b)
Both gypenosides and simvastatin reversed the trend of lipid accumulation in mice livers. HE staining images were enlarged by 40 times.
ND: normal diet group; HFD: high fat diet group; HFD+GP: gypenosides treatment on mice fed with high fat diet; HFD+ST: simvastatin
treatment on mice fed with high fat diet. Data were presented as mean ± SEM. ∗ 𝑝 < 0.05.
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Figure 3: Gypenosides changed the gene expression levels of mouse
hepatic Cyp7a1 and Cyp8b1 which were two rate-limit enzymes of
bile acids biosynthesis. ND: normal diet group; HFD: high fat diet
group; HFD+GP: gypenosides treatment on mice fed with high fat
diet. Data are presented as mean ± SEM. ∗ 𝑝 < 0.05.

3.6. Gypenosides Altered the Expression Levels of Genes
Involved in Enterohepatic Regulation Pathway of Bile Acids
Homeostasis. In mice enterohepatic pathway, the mRNA
levels of all investigated genes were significantly repressed by
high fat diet (Figure 5). After treatment with gypenosides,
gene expression of Jnk1, Jnk2, Erk1, and Erk2 was recovered.
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0
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∗

1.4

Fxr
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HFD
HFD+GP

Figure 4: Gypenosides changed the expression levels of genes
involved in hepatic pathway of bile acids homeostasis regulation.
ND: normal diet treatment; HFD: high fat diet group; HFD+GP:
gypenosides treatment on mice fed with high fat diet. Data are
presented as mean ± SEM. ∗ 𝑝 < 0.05.

However, gene expressions of intestinal Fxr, Fgf15, and
hepatic Fgfr4 were still lower than that in mice treated with
normal diet.
3.7. Effects of Gypenosides on Relative Changes of Bile Acids
in Mice Liver. In the present study, 14 bile acids were quantified in mice livers using LC-MS/MS system. A principle
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Figure 5: Gypenosides changed the expression levels of genes
involved in enterohepatic pathway of bile acids homeostasis regulations. ND: normal diet group; HFD: high fat diet group; HFD+GP:
gypenosides treatment on mice fed with high fat diet. Data are
presented as mean ± SEM. ∗ 𝑝 < 0.05.

component analysis on bile acids data showed that high
fat diet significantly altered the hepatic bile acids profiles
(Figure 6(a)). Component 1 contributed the most to the
location of each mouse. Mice treated with high fat diet shifted
along component 1. After treatment with gypenosides, mice
showed a return trend along component 1; however, they
showed a significant shift along component 2. According to
loading plot (Figure 6(b)), TUDCA, THDCA, and GCDCA
contributed more to HFD group, CA contributed more to
ND group, and TCDCA contributed more to HFD+GP
group. A regular histogram showed the similar trend of
these aforementioned bile acids (Figures 7(a), 7(b), and
7(c)). In addition, CA/CDCA ratio is an important ratio to
evaluate the liver function. Both high fat diet and gypenosides
significantly inhibited the ratio. (Figure 7(d)).

4. Discussion
Animals fed with diet enriching high fat have been widely
used as an experimental model to induce the hyperlipidemia
syndrome [21–23]. In this study, total cholesterol, LDL-C,
and mice body weight levels were significantly increased at
week 16, demonstrating the reliability and reproducibility of
this model. Compared to chemical-induced and transgenic
animal model, high fat diet induced hyperlipidemia model
modulates the related clinic syndromes more precisely [24–
26].
Gypenoside is derived from Gynostemma pentaphyllum
(Thunb.) Makino, a Chinese herbal medicine [27]. To data,
gypenosides ARE reported to reduce the hepatic TC levels
of the hyperlipidemia rats; however, the mechanism is still
not fully understood [28]. In this study, daily administration
of gypenosides for 22 weeks significantly reduced the serum

TC and LDL-C levels, comparable to the effect of simvastatin,
a widely used medication for hypercholesterolemia [29].
Furthermore, gypenosides shared the similar core structures
of bile acids, which are the endogenous ligands of nuclear
receptor FXR, an important regulator of lipid and carbohydrates metabolism [30]. Our studies showed that gypenosides
may reduce serum cholesterol and LDL-C levels via FXR
signaling. Bile acids homeostasis is directly regulated by FXR
via hepatic and enterohepatic pathways. In hepatic pathway,
FXR induces SHP which inhibits LRH1 and HNF4𝛼 [31]. As
LRH1 and HNF4𝛼 are direct inducers of CYP7A1 [32], the
rate-limit enzyme of bile acids biosynthesis, stimulating FXR
would eventually inhibit the generation of bile acids from
cholesterol. On the other hand, once bile acids are excreted
to small intestine via bile duct, intestinal FXR would be
stimulated to enhance the secretion of Fgf15 [33]. The latter
is transported back to liver via the port vein to bind with
hepatic FGFR4, which will subsequently induce Jnk/Erk to
inhibit gene expression of Cyp7a1 [34]. In the present study,
in both hepatic and enterohepatic pathways, we checked the
expression of key genes involving hepatic Cyp7a1, Cyp8b1,
Fxr, Shp, Lrh1, Hnf4𝛼, Jnk1/2, Erk1/2, and Fgfr4, as well as
intestinal Fxr and Fgf15. Data confirmed that gypenosides
significantly altered the expression levels for most of these
genes. Thus, the study results supported our hypothesis that
FXR may be one of the target of gypenosides in mice livers.
CYP7A1 is one of the rate-limiting enzymes involved in
the classic pathway of bile acid biosynthesis. Hepatic SHP
represses the transcription of CYP7A1 by competing with the
nuclear receptor liver receptor homolog 1 (LRH1), which is a
constitutive activator of the Cyp7a1 gene [35]. In this study we
observed that gypenosides decreased the hepatic gene expression levels of Shp in hyperlipidemia mice while they increased
the gene expressions of Cyp7a1 and Lrh1. This implied that
gypenosides may enhance the biosynthesis of bile acids from
cholesterol. Actually, in GP-treated mice, we observed the
increased levels for several abundantly available hepatic bile
acids such as CDCA, DCA, and TDCA. Thus, inhibition of
Shp gene expression accompanied with induction of Cyp7a1
and Lrh1 gene expression and subsequently enhanced the
cholesterol metabolism may be one of the mechanisms of
gypenosides action in reducing serum cholesterol.
The microsomal CYP8B1 enzyme is essential for the
biosynthesis of CA, which regulates CA/CDCA ratio [36].
In the present study, although gypenosides induced Cyp8b1,
the level was still not fully restored. Thus, hepatic CA levels
were still extremely low. On the other hand, the hepatic
CDCA level was higher in the group treated with gypenosides
compared to HFD group. Eventually, GP downregulated the
CA/CDCA ratio compared to both ND and HFD groups. To
data, CA/CDCA ratio is associated with enhanced cholesterol absorption and hypercholesterolemia [37]. Therefore,
restricting the cholesterol absorption may be the other mechanism that explains the impact of gypenosides in reducing
mice serum cholesterol levels.
Accumulation of bile acids leads to hepatic damage
[38]. Enhanced transformation from cholesterol to bile acids
would potentially lead to the accumulation of bile acids in
hepatocytes causing hepatic damage. However, liver damage
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Figure 6: Gypenosides changed the global profile of mouse hepatic bile acids pool. (a) Score plots of principle component analysis on bile
acids profiles. Each spot represents a mouse sample. Gypenosides made the location of mice shift away high fat diet group. ND: normal diet
group; HFD: high fat diet group; HFD+GP: gypenosides treatment on mice fed with high fat diet; (b) loading plots of principle component
analysis. Each spot represents a bile acid. Location of bile acids on loading plots represents its contribution on components.

was not observed in gypenosides-treated mice. The possible
explanation is that free bile acids were subsequently transformed to conjugated bile acids like glycine and taurine conjugation. Glycine-conjugated bile acids may induce reactive
oxygen species and eventually lead to hepatocyte apoptosis
[39]. In the present study, gypenosides kept the pathway of
taurine conjugation on bile acids open but restricted the
glycine conjugation on bile acids. This may be an advantage
of medications developed from gypenosides pool.

Data Availability
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Acknowledgments

Gypenosides significantly improved the abnormal lipid profile in mice treated with high fat diet, while genes regulating
bile acids homeostasis were also changed. Gypenosides may
improve the abnormal lipid profile of HFD-treated mice
via two pathways: (1) enhancing the bile acids biosynthesis
from cholesterol; (2) decreasing the CA/CDCA ratio which
is positively related to cholesterol absorption. As bile acids
regulation is the most sensitive signaling pathway of nuclear
receptor FXR, FXR may be the potential therapeutic target of
gypenosides.

This study was supported by the National Nature
Science Foundation of China (nos. 81560673, 81402985,
and 81660685), Opening Project of Shanghai Key
Laboratory of Complex Prescription (Shanghai University
of Traditional Chinese Medicine) (14DZ2271000), the
Science and Technology Foundation of Guizhou Province
of China (nos. QKHJZ[2015]2158, QKHJZ[2015]2010,
QKHZDZXZ[2015]6010, and QJHKY[2015]373) and Zunyi
City of China (ZSKHSZ[2016]15), Innovative Science and
Technology Projects for Oversea Students in Guizhou

All original data could be found in Supplemental File 2, or
readers could directly send emails to HyqJeff@foxmail.com to
contact Dr. Yuqi He to request the original data and accessing
methods.

Conflicts of Interest
The authors declare no conflicts of interest.

8

Evidence-Based Complementary and Alternative Medicine
1.5

1.5

∗
∗

∗

∗
∗

Fold Change vs ND

∗

∗

1

0.5

0

CA

UDCA

HDCA

CDCA

Fold Change vs ND

∗

1

0.5

0

DCA

GCA

ND
HFD
HFD+GP

GCDCA

2.5
∗

(b)

∗

Ratio of CA to CDCA

Fold Change vs ND

∗

∗
∗

1
0.5

TCA

∗

2

2

0

GDCA

ND
HFD
HFD+GP
(a)

1.5

∗

TUDCA THDCA TCDCA TDCA

TLCA

1.5

1

0.5

0
ND

HFD

HFD+GP

ND
HFD
HFD+GP
(d)

(c)

Figure 7: Mouse hepatic bile acids levels shown as histograms. (a) Gypenosides effect on free bile acids levels. (b) Gypenosides effect on
glycine-conjugated bile acids levels. (c) Gypenosides effect on taurine-conjugated bile acids levels. (d) Gypenosides effect on CA/CDCA
ratio. ND: normal diet group; HFD: high fat diet group; HFD+GP: gypenosides treatment on mice fed with high fat diet. Data were presented
as mean ± SEM. ∗ 𝑝 < 0.05.

Province of China (QRXMZZHT(2015)03H), Program
for Excellent Young Talents of Zunyi Medical University
(15zy-004), and Chunhui Plan of the Ministry of Education
of China (Z2016003).

Supplementary Materials
Supplementary 1. Quality analysis of gypenosides used in the
present study. (A) High performance liquid chromatography
(HPLC) chromatogram of gypenosides. (B) UV spectrum of
represented peaks.
Supplementary 2. Original data of the present study.

References
[1] J. Su, H. Wang, C. Ma et al., “Hypolipidemic mechanism of
gypenosides via inhibition of pancreatic lipase and reduction
in cholesterol micellar solubility,” European Food Research and
Technology, vol. 242, no. 3, pp. 305–312, 2016.
[2] L. Bao, S. Bai, and G. Borijihan, “Hypolipidemic effects of a new
piperine derivative GB-N from Piper longum in high-fat dietfed rats,” Pharmaceutical Biology, vol. 50, no. 8, pp. 962–967,
2012.
[3] J. Wang, J.-L. Yang, P.-P. Zhou, X.-H. Meng, and Y.-P. Shi,
“Further new gypenosides from jiaogulan (Gynostemma pentaphyllum),” Journal of Agricultural and Food Chemistry, vol. 65,
no. 29, pp. 5926–5934, 2017.

Evidence-Based Complementary and Alternative Medicine
[4] D.-J. Chen, H.-G. Hu, S.-F. Xing, Y.-J. Gao, S.-F. Xu, and X.L. Piao, “Metabolic profiling of Gynostemma pentaphyllum
extract in rat serum, urine and faeces after oral administration,”
Journal of Chromatography B, vol. 969, pp. 42–52, 2014.
[5] Q. He, J.-K. Li, F. Li et al., “Mechanism of action of gypenosides
on type 2 diabetes and non-alcoholic fatty liver disease in rats,”
World Journal of Gastroenterology, vol. 21, no. 7, pp. 2058–2066,
2015.
[6] S.-H. Gou, H.-F. Huang, X.-Y. Chen et al., “Lipid-lowering,
hepatoprotective, and atheroprotective effects of the mixture
Hong-Qu and gypenosides in hyperlipidemia with NAFLD
rats,” Journal of the Chinese Medical Association, vol. 79, no. 3,
pp. 111–121, 2016.
[7] S. Megalli, F. Aktan, N. M. Davies, and B. D. Roufogalis,
“Phytopreventive anti-hyperlipidemic effects of Gynostemma
pentaphyllum in rats,” Journal of Pharmacy & Pharmaceutical
Sciences, vol. 8, no. 3, pp. 507–515, 2005.
[8] B. La Cour, P. Mølgaard, and Z. Yi, “Traditional Chinese medicine in treatment of hyperlipidaemia,” Journal of
Ethnopharmacology, vol. 46, no. 2, pp. 125–129, 1995.
[9] R. Qin, J. Zhang, C. Li et al., “Protective effects of gypenosides
against fatty liver disease induced by high fat and cholesterol
diet and alcohol in rats,” Archives of Pharmacal Research, vol.
35, no. 7, pp. 1241–1250, 2012.
[10] J. Yeo, Y. J. Kang, S. M. Jeon et al., “Potential hypoglycemic
effect of an ethanol extract of Gynostemma pentaphyllum in
C57BL/KsJ-db/db mice,” Journal of Medicinal Food, vol. 11, no.
4, pp. 709–716, 2008.
[11] J. Liu, Y. Li, P. Yang et al., “Gypenosides reduced the risk of
overweight and insulin resistance in C57BL/6J mice through
modulating adipose thermogenesis and gut microbiota,” Journal of Agricultural and Food Chemistry, vol. 65, no. 42, pp. 9237–
9246, 2017.
[12] S. Zhuang, Q. Li, L. Cai, C. Wang, and X. Lei, “Chemoproteomic
profiling of bile acid interacting proteins,” ACS Central Science,
vol. 3, no. 5, pp. 501–509, 2017.
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